London, England -- (SBWIRE) -- 03/21/2012 -- In 2010, the global urological disorders market was estimated to be worth $8.1 billion, representing a Compound Annual Growth Rate (CAGR) of 7.9% between 2002 and 2010. In the same year, Urinary Incontinence (UI) and Benign Prostatic Hyperplasia (BPH) combined accounted for 79% of the total urological disorders market with revenue of $6.5 billion. Solifenacin and tolterodine for UI and dutasteride and tamsulosin for BPH dominated the market in 2010 and generated $2 billion and $1.8 billion respectively.

The global urological disorders market is expected to witness a series of patent expiries between 2009 and 2017 which will include most of the top selling blockbuster drugs in the UI, BPH, Urinary Tract Infection (UTI) and Interstitial Cystitis (IC) markets.

Important drugs that have recently lost patent protection include Flomax (tamsulosin, 2009) and Levaquin (levofloxacin, 2010). Those set to lose patent protection in the forecast period include Uroxatral in the US (alfuzosin, 2011), Detrol (tolterodine, 2012), Avodart (dutasteride, 2015), Enablex (darifenacin, 2015) and Ditropan XL (oxybutynin, 2015).

The current urological disorders pipeline does offer some promising novel products, namely URG101, YM178, NX-1207, PRX302 and PSD597, indicated for different segments of the market. The revenues generated from these products are not however expected to completely make up for the revenue losses incurred from patent expiries. Thus, the market is expected to show slow growth during the forecast period.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Urological-Disorders-Therapeutics-to-2017-Large-Number-of-Licensing-Deals-for-Approved-Products-Reflects-a-Pessimistic-RD-Future&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&companyID=sbwire

Johnson & Johnson, Pfizer, GlaxoSmithKline, Astellas Pharma and Sanofi together account for 88% of the total market. Johnson & Johnson leads with a 29% share, and its drugs Levaquin and Elmiron have particularly strong presence in the UTI and UI markets respectively. Pfizer, which has a 19% share, manufactures Detrol which is the most prescribed branded drug worldwide for the symptoms of Overactive Bladder (OAB), namely urinary frequency, urgency and incontinence. GlaxoSmithKline accounts for an 18% share of the market, and manufactures Avodart, which has strong presence in the global BPH market. Astellas Pharma and Sanofi account for 15% and 7% respectively. Other players include Novartis, Bayer, Allergan, Merck and Mutual Pharma among others.

Our new report, “Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future”, provides in-depth analysis of the unmet need, drivers, and barriers that impact the global urological disorders market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Do follow us at facebook:
http://www.facebook.com/PharmaceuticalsandHealthcareMarketIntelligence

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782